semaj83/ctmatch_classification huggingface dataset:
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Irritable Bowel Syndrome Female from 18 to 65 years of age, inclusive Patient experiences recurrent abdominal pain or discomfort at least 3 days per month for the last 3 months with symptom onset at least 6 months prior to diagnosis. The patient's symptoms must be associated with 1 or more of the following Improvement with defecation Onset associated with a change in frequency of stool Onset associated with a change in form (appearance) of stool Negative serum and urine pregnancy tests Completion of at least six days of daily diary assessments using a phone-in information system prior to randomization  Serious underlying diseases, including psychiatric disorders Current history of conditions affecting bowel transit Recent history of biochemical or structural abnormalities of the gastrointestinal tract, gastrointestinal surgery, or gastrointestinal infection Clinically significant abnormal examination findings or laboratory tests Inability to stop taking certain medications, or a planned change in medications (including herbal remedies) which could interfere with study assessments Use of drugs and or ethanol which may interfere with compliance of study procedures or influence study outcome Presence of a medical condition which could interfere with the interpretation of study data Significant use of nicotine or caffeine
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Small Bowel Bacterial Overgrowth Gastrointestinal Diseases Stomach Diseases Digestive System Diseases for Healthy Subjects: 1. Mentally competent and able to give informed consent. 2. Healthy males and females between 18-70 years of age with no current or previous chronic gastrointestinal symptoms. for Symptomatic Subjects: 1. Males and females between 18-70 years of age with symptoms suggestive of small bowel bacterial overgrowth (e.g., diarrhea, bloating, abdominal discomfort) for at least 3 months during the previous 12 months (need not be consecutive) who recently underwent an evaluation for small bowel bacterial overgrowth by either hydrogen breath testing or culture of small bowel aspirate. 2. Ability to stop laxatives and prokinetic and narcotic analgesic agents 3 days prior to the study and during the study period. 3. Ability to stop proton pump inhibitors 7 days prior to the study and histamine type-2 receptor antagonists (H_2RAs) for 3 days prior to the study and during the study period  Subjects who are unable or unwilling to give informed consent or return for all required study visits. 2. Prior gastrointestinal surgery which has altered the anatomy of the esophagus, stomach or small/large intestine (exceptions appendectomy, cholecystectomy and fundoplication). 3. Hypersensitivity to rifaximin. 4. Use of any medications in the previous week that could alter gastrointestinal motor function. 5. Body Mass Index (BMI) > 38. 6. Previous history of bezoars. 7. Any abdominal surgery within the past 3 months. 8. Known or history of inflammatory bowel disease. 9. History of diverticulitis, diverticular stricture, and other intestinal strictures. 10. Tobacco use within eight hours prior to capsule ingestion and during the initial 8 hour recording on the first day. 11. Alcohol use within eight hours prior to capsule ingestion and throughout the entire monitoring period (up to 5 days). 12. Females of childbearing age who are not practicing birth control and/or are pregnant or lactating (A urine pregnancy test will be performed on female subjects prior to capsule ingestion). 13. Cardiovascular, endocrine, renal or other chronic disease likely to affect motility. 14. Use of medical devices such as pacemakers, infusion pumps, or insulin pumps
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Kidney Disease Patients will be eligible for enrollment if they are > 18 year old men or women receiving care from the Renal Clinic with a documented diagnosis of CKD stage 2-5, and are receiving pharmacological treatment for one or more medical conditions of CKD, including hypertension, diabetes, CKD-mineral and bone disorders, and/or anemia of chronic disease  Patients will be excluded from the study if they obtain medications prescribed for the above medical conditions from a facility outside the are enrolled in Medi-Set clinic, are kidney transplant patients, are diagnosed with CKD stage 1, require assistance in the administration of their medications (i.e. caregiver), lack adequate transportation to clinic, and/or lack telephone access
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 19.0-53.0,  Healthy The sample size will be 90 healthy men (n=30/group) based on the following Healthy body weight based on body mass index (18.5 kg/m2 as per Health Canada No chronic diseases Normal bone mass for age (ie Z-score better than -1 where reference data available) Vitamin D status within optimal range based on serum 25(OH)D (between 50 and 80 nmol/L of serum 25(OH)D with a median threshold of 75 nmol/L as set by international experts
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Pain The subject is 18 to 75 years old The subject is an ambulatory outpatient The subject has IBS, or functional diarrhea, or functional bloating according to the Rome II for functional GI disorders The subject has the above symptoms for at least two weeks, despite current therapy. For diarrhea, we will use the definition of a mean of >2 bowel movements per day, or a mean score of > 4 on the Bristol Stool Form Scale per week. For bloating we will use the Rome II definition "a feeling of abdominal fullness or bloating" Subject must have had a colonoscopy if age > 50y/o The subject's symptoms are mild to moderate symptoms in severity. Symptoms severity will be assessed at baseline and at the end of the 2-weeks screening period to determine prior randomization. Severity of bowel symptoms will be determined using the Francis Whorwell IBS severity scale: Mild <175, Moderate 175-300, Severe >300  The subject has inflammation or structural abnormality of the digestive tract (e.g. inflammatory bowel disease (IBD), duodenal ulcer (DU) or gastric ulcer (GU), obstruction, symptomatic cholelithiasis) The subject has severe FBD related symptoms at baseline The subject has a serious, unstable medical condition The subject has insulin-dependent Diabetes Mellitus The subject had a major psychiatric diagnosis or a suicide attempt within the last two years The subject has a history of alcohol or substance abuse within two years The subject has abnormal laboratory results (including ALT or AST > than 2.5 times normal, serum creatinine >2.0mg/dl, untreated abnormal TSH value) The subject has been treated for a malignancy within the last 5 years (except BCC or SCC skin cancer) The subject has been diagnosed with lactase deficiency and this can explain their symptoms (i.e., symptoms resolved or reduced significantly with lactose-free diet.) The subject has participated in a drug study within the last 21 days
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 0.75-1.0,  Cholera Diarrhea Vibrio Infections Healthy male and female infants aged 9 months will be recruited from Vellore, India and Dhaka, Bangladesh. All subjects must satisfy the following at study entry: 1. Male or female infants aged 9 months whose parents or primary caretaker have given the written informed consent prior to study entry 2. Will comply with the requirements of the protocol (i.e. available for follow-up visits and specimen collection). 3. Healthy subjects as determined by Medical history Physical examination Clinical judgment of the investigator  Parents or primary caregiver are unwilling or unable to give written informed consent to participate in the study 2. Ongoing serious chronic disease 3. Immunocompromising condition or therapy 4. Abdominal pain or cramps, loss of appetite, nausea, general ill-feeling or vomiting in the past 24 hours 5. Intake of any anti-diarrheal medicine in the past week 6. Acute disease one week prior to enrollment, with or without fever. Temperature ≥38ºC (oral) or axillary temperature ≥ 37.5ºC warrants deferral of the vaccination pending recovery of the subject 7. Receipt of antibiotics in the past 2 weeks 8. Receipt of live or killed enteric vaccine in the last 4 weeks 9. Diarrhea (3 or more loose stools within a 24-hour period) 6 weeks prior to enrollment 10. One or two episodes of diarrhea lasting for more than 2 weeks in the past 6 months 11. One or two episodes of abdominal pain lasting for more than 2 weeks in the past 6 months 12. Receipt of killed oral cholera vaccine 13. Have previously received a dose of a measles-containing vaccine (MCV) 14. Have previously presented with a disease potentially related to measles 15. Receipt of blood, blood products or a parenteral immunoglobulin preparation in the previous 3 months 16. History of anaphylaxis, any serious vaccine reaction, allergy to eggs, egg products or to any measles vaccine component 17. any condition which in the opinion of the investigator, might interfere with the evaluation of the study objectives
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 7.0-60.0,  Exocrine Pancreatic Insufficiency Steatorrhea Malabsorption Syndromes Cystic Fibrosis Have a diagnosis of CF documented by sweat chloride results (>60 mmol/L) and require pancreatic enzyme replacement therapy (PERT) to control clinical symptoms of EPI (nausea, vomiting, bloating, diarrhea, and abdominal pain) with a history of excess fat in the feces Have documentation of an abnormal COA-fat and a fecal elastase result of <100 micrograms fecal elastase/gram stool Must be on a stable diet and dose of pancreatic enzyme supplementation that has provided satisfactory symptom control for at least the past 1 month  No extreme physical wasting with loss of weight and muscle mass No severe, acute, or chronic pulmonary disease unrelated to complications of CF No worsening of pulmonary disease in past 30 days No use of drugs known to affect blood uric acid concentrations (e.g., aspirin, diflunisal, allopurinol, probenecid, thiazide diuretics, phenylbutazone, sulfinpyrazone) No known congenital (present at birth) abnormalities of the gastrointestinal tract, heart, or liver No distal intestinal obstruction syndrome (DIOS)
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Diverticulosis, Colonic Symptomatic diverticular disease with short lived recurrent abdominal pain on 3 or more days a month years of age Signed informed consent Presence of at least one diverticulum in the left colon  Pregnant or lactating women Severe co-morbidity, alcoholism or drug dependence or inability to give informed consent Contraindications to use of Mesalazine as detailed in SmPC Inability to stop NSAIDs (non-steroidal anti-inflammatory agents) or long term antibiotics The use of specific concomitant medications as detailed in the section below Presence of other gastrointestinal inflammatory conditions such as ulcerative colitis, Crohn's disease and Coeliac disease
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Stage I Bladder Cancer Stage II Bladder Cancer Stage III Bladder Cancer Diagnosis of bladder cancer Bladder tumor discovered on cystoscopy within the past 60 days Invasive or non-invasive tumor Primary tumor may represent either an initial diagnosis or recurrent disease of any clinical stage No metastatic disease Must be an eligible candidate for a partial cystectomy, radical cystectomy, or trans-urethral resection of bladder tumor (TURBT) Has not undergone any treatment for superficial or invasive bladder cancer since the diagnostic cystoscopy TURBT or radical cystectomy is the planned curative surgical treatment ECOG performance status (PS) 0-1 OR Karnofsky PS 70-100% More than 30 days since any prior intravesical therapy or adjuvant chemotherapy
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Cholera Age: 15 years Gender: Male (women would be excluded due to difficulties in separation of their urine from stools, particularly in those with severely dehydrated and associated mental obtundation) Duration of diarrhoea: 24 hours or less Clinical signs and symptoms of severe dehydration Demonstration of V. cholerae in dark-field microscopy of a fresh stool specimen Written informed consent for participation in the study (for patients with temporary inability to provide consent due to their severe dehydration and mental obtundation, initial consent would be obtained from their attendants; however, the consent process would be re-applied to the patients when they are fully oriented)  Chronic or iatrogenic diarrhoea Dysentery (presence of visible blood in stool) History of receiving antimicrobial or antidiarrhoeal drugs prior to admission Presence of concomitant infection or underlying disease, which might complicate diagnosis and/or assessment of response to study interventions History of renal or hepatic dysfunction Failure to obtain informed consent
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 0.5-5.0,  Incidence of Acute Diarrhea Incidence of Abdominal Pain Children 6 months to 5 years of age Presented with passage of 3 or more loose or watery stools Caretakers are willing to let their child to participate in the study  Failure to produce consent Children with severe malnutrition or having chronic illness
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Diarrhea Diagnosis of acute diarrhea with gas-related abdominal discomfort, meeting specific Willing to follow the protocol requirements and comply with protocol restrictions, including use of contraception Able to understand the informed consent process and sign the form Cooperative, reliable and willing to comply with the protocol requirements and schedule, and able to record efficacy and safety assessments  Female subjects who are pregnant, lactating or experiencing perimenstrual abdominal or pelvic discomfort Illness requires hospitalization, IV fluids or antibiotics Has taken antibiotics in the past 7 days or a symptomatic antidiarrheal compound in the past 12 hours or any analgesic in the past 6 hours History of significant underlying enteric, pulmonary, hepatic, cardiac, renal disease, seizure disorder, IBD, cancer, uncontrolled diabetes, or any other unstable medical condition History of hypersensitivity to loperamide or simethicone Has previously participated in this study or received an investigational drug within the 30 day period before screening